This document discusses the rationale for using luteinizing hormone (LH) for ovulation induction and superovulation. It notes that LH plays an important role in the mid-follicular phase by regulating theca cell function and androgen production, which is necessary for follicular development. The concept of an optimal "therapeutic window" of LH levels is introduced, with both insufficient and excessive LH being detrimental to follicular growth and oocyte maturation. Certain patient groups, such as poor responders, older women, and those with LH polymorphisms, may benefit from LH supplementation during assisted reproductive technology cycles to improve outcomes.